The U.S.-listed shares of Shire PLC fell 1.2% in premarket trade Tuesday, after the Ireland-based drug maker said a phase 2/3 trial of its treatment for Hunter syndrome in pediatric patients failed to meet its primary and secondary endpoints. The company said it will continue its dialogue with the trial community as it analyzes the trial data, and will present further analysis in the future. “Shire is disappointed that the top-line data from this study did not meet the primary and key secondary endpoints and remains committed to patients and families living with MPS II,” said Howard Meyer, global head of research and development. The stock has lost 10.9% year to date through Monday, while the SPDR S&P Pharmaceutical ETF has gained 11.5% and the S&P 500 has climbed 20.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News